Secondary Malignant Neoplasm

Observed

← altered in cohorts of

GLB1

450 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

PLXNB1

450 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

ATRIP

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

CCDC51

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

CDC25A

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

CELSR3

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

FBXW12

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

HHATL

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

IP6K2

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

NCKIPSD

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

PFKFB4

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

PRKAR2A

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

PTH1R

449 / 536 cases (84 %) · ssm · TCGA-KIRC

—

Observed

← altered in cohorts of

SCN5A

449 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts

—

Observed

Secondary Malignant Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived200 of 331show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal antibody 346 trials (162 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	346	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 259 trials (92 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	259	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 220 trials (90 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	220	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 216 trials (87 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	216	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 189 trials (14 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	189	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 186 trials (83 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	186	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 178 trials (67 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	178	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 172 trials (48 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	172	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 155 trials (40 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	155	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 152 trials (66 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	152	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 114 trials (28 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 109 trials (32 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	109	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 107 trials (55 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 105 trials (37 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	105	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 101 trials (59 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	101	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 101 trials (28 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	101	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 92 trials (34 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	92	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 89 trials (48 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	89	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 87 trials (47 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	87	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 79 trials (26 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	79	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 75 trials (20 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	75	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 67 trials (13 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	67	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 66 trials (19 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Sintilimabmonoclonal antibody 65 trials (31 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	65	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 58 trials (31 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 57 trials (18 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Tremelimumabmonoclonal antibody 52 trials (28 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 50 trials (21 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	50	Observed	clinicaltrials	graph →
→ investigated in trials for	Toripalimabmonoclonal antibody 47 trials (22 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	47	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 44 trials (26 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 44 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Camrelizumabmonoclonal antibody 42 trials (16 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 38 trials (16 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinib Hydrochloridesmall molecule 34 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenib Tosylatesmall molecule 34 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Axitinibsmall molecule 33 trials (13 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 33 trials (11 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Enzalutamidesmall molecule 32 trials (10 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Regorafenibsmall molecule 32 trials (11 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Avelumabmonoclonal antibody 31 trials (9 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Leuprolideother 31 trials (14 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 31 trials (7 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Cemiplimabmonoclonal antibody 27 trials (19 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Goserelinother 27 trials (13 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinibsmall molecule 26 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 25 trials (11 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 24 trials (11 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Lutetium (177lu) Oxodotreotideother 24 trials (11 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 23 trials (7 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Pazopanibsmall molecule 22 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Abiraterone Acetatesmall molecule 21 trials (11 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Aldesleukinother 21 trials (8 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Metforminsmall molecule 21 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Abemaciclibsmall molecule 20 trials (9 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Temsirolimussmall molecule 19 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 19 trials (6 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Apalutamidesmall molecule 18 trials (11 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 18 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Palbociclibsmall molecule 17 trials (7 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 16 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 16 trials (9 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 16 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Gefitinibsmall molecule 15 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 15 trials (8 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Ramucirumabmonoclonal antibody 15 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Veliparibsmall molecule 15 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Azacitidinesmall molecule 14 trials (8 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 14 trials (7 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Dasatinibsmall molecule 14 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 14 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Tamoxifensmall molecule 14 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Vorinostatsmall molecule 14 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Afatinibsmall molecule 13 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Decitabinesmall molecule 13 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Degarelixother 13 trials (9 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Epirubicinsmall molecule 13 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Fulvestrantsmall molecule 13 trials (7 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 13 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Thalidomidesmall molecule 13 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Trametinibsmall molecule 13 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Vandetanibsmall molecule 13 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 13 trials (8 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Panitumumabmonoclonal antibody 12 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Pertuzumabmonoclonal antibody 12 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Sirolimussmall molecule 12 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Adebrelimabmonoclonal antibody 11 trials (8 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Eribulinsmall molecule 11 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 11 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Retifanlimabmonoclonal antibody 11 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Ruxolitinibsmall molecule 11 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Abirateronesmall molecule 10 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabazitaxelsmall molecule 10 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cixutumumabmonoclonal antibody 10 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	FOLFOX Regimen 10 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Lapatinibsmall molecule 10 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Nimotuzumabmonoclonal antibody 10 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Pasireotideother 10 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Ribociclibsmall molecule 10 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Hydroxychloroquinesmall molecule 9 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 9 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Pegargiminaseother 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Pegfilgrastimother 9 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Selumetinibsmall molecule 9 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Akt Inhibitor MK2206 8 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Belzutifansmall molecule 8 trials (7 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Cobimetinibsmall molecule 8 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Copanlisibsmall molecule 8 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Flutamidesmall molecule 8 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Mitomycinsmall molecule 8 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Talazoparibsmall molecule 8 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Adavosertibsmall molecule 7 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Alisertibsmall molecule 7 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Alpelisibsmall molecule 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Belinostatsmall molecule 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Binimetinibsmall molecule 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	FOLFOX-4 Regimen 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Nintedanibsmall molecule 7 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Relugolixsmall molecule 7 trials (7 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Romidepsinother 7 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Sacituzumab Govitecanadc 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Selpercatinibsmall molecule 7 trials (6 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Serplulimabmonoclonal antibody 7 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Anastrozolesmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Capivasertibsmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Daunorubicinsmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Dostarlimabmonoclonal antibody 6 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Exemestanesmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Ganitumabmonoclonal antibody 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Hydroxyureasmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Idarubicinsmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Immune Checkpoint Inhibitor 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Neratinibsmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Osimertinibsmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Tegafursmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Tipifarnibsmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Tivozanibsmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Triptorelinother 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Zoledronic Acidsmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Anti-PD1 Monoclonal Antibody 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Berzosertibsmall molecule 5 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenibsmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	FOLFIRI Regimen 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Ganetespibsmall molecule 5 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Hormone Therapy 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumab/Nivolumab Regimen 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lurbinectedinsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lutetium (177lu) Vipivotide Tetraxetanother 5 trials (5 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Pralsetinibsmall molecule 5 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Rucaparibsmall molecule 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Sapanisertibsmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Tarlatamabmonoclonal antibody 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Tazemetostatsmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Vismodegibsmall molecule 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Afliberceptother 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Alvocidibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Arsenic Trioxidesmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Buparlisibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Capmatinibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Celecoxibsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Crizotinibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Fruquintinibsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Histrelinother 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Icotinibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Immunotherapy 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipatasertibsmall molecule 4 trials (4 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Poziotinibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Selinexorsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Sonidegibsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Talimogene Laherparepvecgene therapy 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Valproic Acidsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Vemurafenibsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Vinorelbinesmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Amivantamabmonoclonal antibody 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Aspirinsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ceritinibsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Clofarabinesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Daratumumabmonoclonal antibody 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Darolutamidesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Denosumabmonoclonal antibody 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Disitamab Vedotinadc 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Dovitinibsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Elimusertibsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Enasidenibsmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Enfortumab Vedotinadc 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Entrectinibsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Estramustinesmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Firmonertinibsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Guadecitabinesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Lifileucelcell therapy 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Mitoxantronesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Nilutamidesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Panobinostatsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Peginterferon Alfa-2bother 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ponatinibsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Porfimer 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	3	Observed	clinicaltrials	graph →

Secondary Malignant Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived200 of 331show all (up to 200)

→ investigated in trials for

Pembrolizumabmonoclonal antibody

346 trials (162 active) · roll-up of the cancer and its descendants

—

346

Observed

→ investigated in trials for

Cisplatinsmall molecule

259 trials (92 active) · roll-up of the cancer and its descendants

—

259

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

220 trials (90 active) · roll-up of the cancer and its descendants

—

220

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

216 trials (87 active) · roll-up of the cancer and its descendants

—

216

Observed

→ investigated in trials for

Sorafenibsmall molecule

189 trials (14 active) · roll-up of the cancer and its descendants

—

189

Observed

→ investigated in trials for

Carboplatinsmall molecule

186 trials (83 active) · roll-up of the cancer and its descendants

—

186

Observed

→ investigated in trials for

Paclitaxelsmall molecule

178 trials (67 active) · roll-up of the cancer and its descendants

—

178

Observed

→ investigated in trials for

Gemcitabinesmall molecule

172 trials (48 active) · roll-up of the cancer and its descendants

—

172

Observed

→ investigated in trials for

Fluorouracilsmall molecule

155 trials (40 active) · roll-up of the cancer and its descendants

—

155

Observed

→ investigated in trials for

Lenvatinibsmall molecule

152 trials (66 active) · roll-up of the cancer and its descendants

—

152

Observed

→ investigated in trials for

Cetuximabmonoclonal antibody

114 trials (28 active) · roll-up of the cancer and its descendants

—

114

Observed

→ investigated in trials for

Docetaxelsmall molecule

109 trials (32 active) · roll-up of the cancer and its descendants

—

109

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

107 trials (55 active) · roll-up of the cancer and its descendants

—

107

Observed

→ investigated in trials for

Nab-paclitaxel

105 trials (37 active) · roll-up of the cancer and its descendants

—

105

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

101 trials (59 active) · roll-up of the cancer and its descendants

—

101

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

101 trials (28 active) · roll-up of the cancer and its descendants

—

101

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

92 trials (34 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

89 trials (48 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

87 trials (47 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall molecule

79 trials (26 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall molecule

75 trials (20 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

67 trials (13 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

66 trials (19 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sintilimabmonoclonal antibody

65 trials (31 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal antibody

58 trials (31 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

57 trials (18 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tremelimumabmonoclonal antibody

52 trials (28 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

50 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Toripalimabmonoclonal antibody

47 trials (22 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall molecule

44 trials (26 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

44 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Camrelizumabmonoclonal antibody

42 trials (16 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Prednisonesmall molecule

38 trials (16 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinib Hydrochloridesmall molecule

34 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

34 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Axitinibsmall molecule

33 trials (13 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trastuzumabmonoclonal antibody

33 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enzalutamidesmall molecule

32 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Regorafenibsmall molecule

32 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avelumabmonoclonal antibody

31 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leuprolideother

31 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pemetrexedsmall molecule

31 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cemiplimabmonoclonal antibody

27 trials (19 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Goserelinother

27 trials (13 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinibsmall molecule

26 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

25 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Chemotherapy

24 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lutetium (177lu) Oxodotreotideother

24 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bicalutamidesmall molecule

23 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pazopanibsmall molecule

22 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abiraterone Acetatesmall molecule

21 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aldesleukinother

21 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Metforminsmall molecule

21 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abemaciclibsmall molecule

20 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

19 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

19 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Apalutamidesmall molecule

18 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temozolomidesmall molecule

18 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Palbociclibsmall molecule

17 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

16 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cediranibsmall molecule

16 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

16 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gefitinibsmall molecule

15 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Letrozolesmall molecule

15 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ramucirumabmonoclonal antibody

15 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

15 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Azacitidinesmall molecule

14 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cytarabinesmall molecule

14 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dasatinibsmall molecule

14 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

14 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tamoxifensmall molecule

14 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

14 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Afatinibsmall molecule

13 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Decitabinesmall molecule

13 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Degarelixother

13 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Epirubicinsmall molecule

13 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fulvestrantsmall molecule

13 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall molecule

13 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Thalidomidesmall molecule

13 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trametinibsmall molecule

13 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vandetanibsmall molecule

13 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Venetoclaxsmall molecule

13 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Panitumumabmonoclonal antibody

12 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pertuzumabmonoclonal antibody

12 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sirolimussmall molecule

12 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Adebrelimabmonoclonal antibody

11 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Eribulinsmall molecule

11 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Melphalansmall molecule

11 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Retifanlimabmonoclonal antibody

11 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ruxolitinibsmall molecule

11 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abirateronesmall molecule

10 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabazitaxelsmall molecule

10 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cixutumumabmonoclonal antibody

10 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

FOLFOX Regimen

10 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lapatinibsmall molecule

10 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nimotuzumabmonoclonal antibody

10 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pasireotideother

10 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ribociclibsmall molecule

10 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Hydroxychloroquinesmall molecule

9 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall molecule

9 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall molecule

9 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegargiminaseother

9 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegfilgrastimother

9 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selumetinibsmall molecule

9 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Akt Inhibitor MK2206

8 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Belzutifansmall molecule

8 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cobimetinibsmall molecule

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Copanlisibsmall molecule

8 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Flutamidesmall molecule

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mitomycinsmall molecule

8 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Talazoparibsmall molecule

8 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Adavosertibsmall molecule

7 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alisertibsmall molecule

7 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alpelisibsmall molecule

7 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Belinostatsmall molecule

7 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Binimetinibsmall molecule

7 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Busulfansmall molecule

7 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

FOLFOX-4 Regimen

7 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nintedanibsmall molecule

7 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Relugolixsmall molecule

7 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Romidepsinother

7 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sacituzumab Govitecanadc

7 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selpercatinibsmall molecule

7 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Serplulimabmonoclonal antibody

7 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Anastrozolesmall molecule

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capivasertibsmall molecule

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Daunorubicinsmall molecule

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dostarlimabmonoclonal antibody

6 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Exemestanesmall molecule

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ganitumabmonoclonal antibody

6 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Hydroxyureasmall molecule

6 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Idarubicinsmall molecule

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

Immune Checkpoint Inhibitor

→ investigated in trials for

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Neratinibsmall molecule

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Osimertinibsmall molecule

6 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rituximabmonoclonal antibody

6 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tegafursmall molecule

6 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tipifarnibsmall molecule

6 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tivozanibsmall molecule

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Triptorelinother

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Zoledronic Acidsmall molecule

6 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Anti-PD1 Monoclonal Antibody

→ investigated in trials for

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Berzosertibsmall molecule

5 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dabrafenibsmall molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

FOLFIRI Regimen

5 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ganetespibsmall molecule

5 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Hormone Therapy

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

Ipilimumab/Nivolumab Regimen

→ investigated in trials for

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lurbinectedinsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lutetium (177lu) Vipivotide Tetraxetanother

5 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pralsetinibsmall molecule

5 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rucaparibsmall molecule

5 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sapanisertibsmall molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tarlatamabmonoclonal antibody

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tazemetostatsmall molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vismodegibsmall molecule

5 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Afliberceptother

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alvocidibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Arsenic Trioxidesmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Buparlisibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capmatinibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Celecoxibsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Crizotinibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fruquintinibsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Histrelinother

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Icotinibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imatinibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Immunotherapy

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipatasertibsmall molecule

4 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Poziotinibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selinexorsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sonidegibsmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Talimogene Laherparepvecgene therapy

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Valproic Acidsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vemurafenibsmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinorelbinesmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Amivantamabmonoclonal antibody

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aspirinsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ceritinibsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Clofarabinesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Daratumumabmonoclonal antibody

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Darolutamidesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Denosumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Disitamab Vedotinadc

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dovitinibsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Elimusertibsmall molecule

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enasidenibsmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enfortumab Vedotinadc

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Entrectinibsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Estramustinesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Firmonertinibsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Guadecitabinesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lifileucelcell therapy

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mitoxantronesmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nilutamidesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Panobinostatsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Peginterferon Alfa-2bother

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ponatinibsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Porfimer

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Secondary Malignant Neoplasm studied in …STUDIED_INderived10 of 7,780show all (up to 200)
→ studied in	NCT00423306Phase 2 · completed A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02743741NA · completed Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 7,780 trials mapped (2,638 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Breast Inflammatory Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Collecting Duct Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03897543Phase 1/Phase 2 · completed ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 7,780 trials mapped (2,638 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 7,780 trials mapped (2,638 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →

Secondary Malignant Neoplasm studied in …STUDIED_INderived10 of 7,780show all (up to 200)

→ studied in

NCT00423306Phase 2 · completed

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)

—

Hepatocellular Carcinoma

Observed

Fallopian Tube Endometrioid Adenocarcinoma

→ studied in

NCT02345265Phase 2 · active not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)

—

Observed

Fallopian Tube Clear Cell Adenocarcinoma

→ studied in

NCT02446600Phase 3 · active not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)

—

Observed

Fallopian Tube Clear Cell Adenocarcinoma

→ studied in

NCT02502266Phase 2/Phase 3 · active not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)

—

Observed

→ studied in

NCT02743741NA · completed

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)

—

Neuroendocrine Tumor

Observed

Ovarian Endometrioid Adenocarcinoma

→ studied in

NCT03348631Phase 2 · active not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 7,780 trials mapped (2,638 active)

—

Observed

Breast Inflammatory Carcinoma

→ studied in

NCT03598257Phase 2 · active not recruiting

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)

—

Observed

Collecting Duct Carcinoma

→ studied in

NCT03866382Phase 2 · recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)

—

Observed

→ studied in

NCT03897543Phase 1/Phase 2 · completed

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 7,780 trials mapped (2,638 active)

—

Hepatocellular Carcinoma

Observed

→ studied in

NCT04175912Phase 2 · active not recruiting

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 7,780 trials mapped (2,638 active)

—

Hepatocellular Carcinoma

Observed